FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992076192> ?p ?o ?g. }

• W1992076192 endingPage "376" @default.
• W1992076192 startingPage "369" @default.
• W1992076192 abstract "Purpose To investigate the safety of boronophenylalanine-mediated boron neutron capture therapy (BNCT) in the treatment of malignant gliomas that progress after surgery and conventional external beam radiation therapy. Methods and Materials Adult patients who had histologically confirmed malignant glioma that had progressed after surgery and external beam radiotherapy were eligible for this Phase I study, provided that >6 months had elapsed from the last date of radiation therapy. The first 10 patients received a fixed dose, 290 mg/kg, of l-boronophenylalanine-fructose (l-BPA-F) as a 2-hour infusion before neutron irradiation, and the remaining patients were treated with escalating doses of l-BPA-F, either 350 mg/kg, 400 mg/kg, or 450 mg/kg, using 3 patients on each dose level. Adverse effects were assessed using National Cancer Institute Common Toxicity Criteria version 2.0. Results Twenty-two patients entered the study. Twenty subjects had glioblastoma, and 2 patients had anaplastic astrocytoma, and the median cumulative dose of prior external beam radiotherapy was 59.4 Gy. The maximally tolerated l-BPA-F dose was reached at the 450 mg/kg level, where 4 of 6 patients treated had a grade 3 adverse event. Patients who were given >290 mg/kg of l-BPA-F received a higher estimated average planning target volume dose than those who received 290 mg/kg (median, 36 vs. 31 Gy [W, i.e., a weighted dose]; p = 0.018). The median survival time following BNCT was 7 months. Conclusions BNCT administered with an l-BPA-F dose of up to 400 mg/kg as a 2-hour infusion is feasible in the treatment of malignant gliomas that recur after conventional radiation therapy. To investigate the safety of boronophenylalanine-mediated boron neutron capture therapy (BNCT) in the treatment of malignant gliomas that progress after surgery and conventional external beam radiation therapy. Adult patients who had histologically confirmed malignant glioma that had progressed after surgery and external beam radiotherapy were eligible for this Phase I study, provided that >6 months had elapsed from the last date of radiation therapy. The first 10 patients received a fixed dose, 290 mg/kg, of l-boronophenylalanine-fructose (l-BPA-F) as a 2-hour infusion before neutron irradiation, and the remaining patients were treated with escalating doses of l-BPA-F, either 350 mg/kg, 400 mg/kg, or 450 mg/kg, using 3 patients on each dose level. Adverse effects were assessed using National Cancer Institute Common Toxicity Criteria version 2.0. Twenty-two patients entered the study. Twenty subjects had glioblastoma, and 2 patients had anaplastic astrocytoma, and the median cumulative dose of prior external beam radiotherapy was 59.4 Gy. The maximally tolerated l-BPA-F dose was reached at the 450 mg/kg level, where 4 of 6 patients treated had a grade 3 adverse event. Patients who were given >290 mg/kg of l-BPA-F received a higher estimated average planning target volume dose than those who received 290 mg/kg (median, 36 vs. 31 Gy [W, i.e., a weighted dose]; p = 0.018). The median survival time following BNCT was 7 months. BNCT administered with an l-BPA-F dose of up to 400 mg/kg as a 2-hour infusion is feasible in the treatment of malignant gliomas that recur after conventional radiation therapy." @default.
• W1992076192 created "2016-06-24" @default.
• W1992076192 creator A5004993292 @default.
• W1992076192 creator A5005486763 @default.
• W1992076192 creator A5007349709 @default.
• W1992076192 creator A5014210865 @default.
• W1992076192 creator A5023969604 @default.
• W1992076192 creator A5027991427 @default.
• W1992076192 creator A5029336142 @default.
• W1992076192 creator A5030095223 @default.
• W1992076192 creator A5054430402 @default.
• W1992076192 creator A5070171307 @default.
• W1992076192 creator A5072791614 @default.
• W1992076192 creator A5074881604 @default.
• W1992076192 creator A5077178999 @default.
• W1992076192 creator A5090618504 @default.
• W1992076192 creator A5091615721 @default.
• W1992076192 date "2011-06-01" @default.
• W1992076192 modified "2023-10-16" @default.
• W1992076192 title "l-Boronophenylalanine-Mediated Boron Neutron Capture Therapy for Malignant Glioma Progressing After External Beam Radiation Therapy: A Phase I Study" @default.
• W1992076192 cites W1959628099 @default.
• W1992076192 cites W1972983262 @default.
• W1992076192 cites W1975258721 @default.
• W1992076192 cites W1978025510 @default.
• W1992076192 cites W1991265681 @default.
• W1992076192 cites W1992180571 @default.
• W1992076192 cites W1992893200 @default.
• W1992076192 cites W1993912959 @default.
• W1992076192 cites W1995092870 @default.
• W1992076192 cites W2001660159 @default.
• W1992076192 cites W2002879660 @default.
• W1992076192 cites W2006990003 @default.
• W1992076192 cites W2033996844 @default.
• W1992076192 cites W2034148500 @default.
• W1992076192 cites W2044538065 @default.
• W1992076192 cites W2047885350 @default.
• W1992076192 cites W2050756955 @default.
• W1992076192 cites W2055519675 @default.
• W1992076192 cites W2067043175 @default.
• W1992076192 cites W2079784437 @default.
• W1992076192 cites W2088472732 @default.
• W1992076192 cites W2090046394 @default.
• W1992076192 cites W2096287682 @default.
• W1992076192 cites W2103875971 @default.
• W1992076192 cites W2106795140 @default.
• W1992076192 cites W2139248078 @default.
• W1992076192 cites W2142312148 @default.
• W1992076192 cites W2145030327 @default.
• W1992076192 cites W2147522400 @default.
• W1992076192 cites W2158681922 @default.
• W1992076192 cites W2310815110 @default.
• W1992076192 doi "https://doi.org/10.1016/j.ijrobp.2010.02.031" @default.
• W1992076192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21236605" @default.
• W1992076192 hasPublicationYear "2011" @default.
• W1992076192 type Work @default.
• W1992076192 sameAs 1992076192 @default.
• W1992076192 citedByCount "87" @default.
• W1992076192 countsByYear W19920761922012 @default.
• W1992076192 countsByYear W19920761922013 @default.
• W1992076192 countsByYear W19920761922014 @default.
• W1992076192 countsByYear W19920761922015 @default.
• W1992076192 countsByYear W19920761922016 @default.
• W1992076192 countsByYear W19920761922017 @default.
• W1992076192 countsByYear W19920761922018 @default.
• W1992076192 countsByYear W19920761922019 @default.
• W1992076192 countsByYear W19920761922020 @default.
• W1992076192 countsByYear W19920761922021 @default.
• W1992076192 countsByYear W19920761922022 @default.
• W1992076192 countsByYear W19920761922023 @default.
• W1992076192 crossrefType "journal-article" @default.
• W1992076192 hasAuthorship W1992076192A5004993292 @default.
• W1992076192 hasAuthorship W1992076192A5005486763 @default.
• W1992076192 hasAuthorship W1992076192A5007349709 @default.
• W1992076192 hasAuthorship W1992076192A5014210865 @default.
• W1992076192 hasAuthorship W1992076192A5023969604 @default.
• W1992076192 hasAuthorship W1992076192A5027991427 @default.
• W1992076192 hasAuthorship W1992076192A5029336142 @default.
• W1992076192 hasAuthorship W1992076192A5030095223 @default.
• W1992076192 hasAuthorship W1992076192A5054430402 @default.
• W1992076192 hasAuthorship W1992076192A5070171307 @default.
• W1992076192 hasAuthorship W1992076192A5072791614 @default.
• W1992076192 hasAuthorship W1992076192A5074881604 @default.
• W1992076192 hasAuthorship W1992076192A5077178999 @default.
• W1992076192 hasAuthorship W1992076192A5090618504 @default.
• W1992076192 hasAuthorship W1992076192A5091615721 @default.
• W1992076192 hasConcept C121332964 @default.
• W1992076192 hasConcept C126322002 @default.
• W1992076192 hasConcept C141071460 @default.
• W1992076192 hasConcept C151032500 @default.
• W1992076192 hasConcept C152568617 @default.
• W1992076192 hasConcept C197934379 @default.
• W1992076192 hasConcept C2778227246 @default.
• W1992076192 hasConcept C2778880634 @default.
• W1992076192 hasConcept C2779083369 @default.
• W1992076192 hasConcept C29730261 @default.
• W1992076192 hasConcept C2989005 @default.
• W1992076192 hasConcept C30421969 @default.
• W1992076192 hasConcept C502942594 @default.

• next